Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors

Original Article

J.A. Chan, S. Geyer, T. Zemla, M.V. Knopp, S. Behr, S. Pulsipher, F.-S. Ou, A.C. Dueck, J. Acoba, A. Shergill, E.M. Wolin, T.R. Halfdanarson, B. Konda, N.A. Trikalinos, B. Tawfik, N. Raj, S. Shaheen, N. Vijayvergia, A. Dasari, J.R. Strosberg, E.C. Kohn, M.H. Kulke, E.M. O’Reilly, and J.A. Meyerhardt

N Engl J Med 2025;392:653-665

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit
  • 1.00 Participation
Course opens: 
02/12/2025
Course expires: 
02/13/2027

Available Credit

  • 1.00 AMA PRA Category 1 Credit
  • 1.00 Participation
Please sign in or create an account to take the course.